
|Articles|November 7, 2012
Device delivers glaucoma medication
In a pilot phase II study, an intracanalicular plug (OTX-TP2, Ocular Therapeutics) shows promise for lowering IOP and increasing compliance with the treatment regimen.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA guidance to help accelerate cell and gene therapies
2
Oculis phase 3 DIAMOND trials miss vision endpoints in diabetic macular edema
3
The Residency Report: Cardiovascular risk scores as a window into ocular disease
4
TearSolutions advances Lacripep into phase 2 following dual FDA designations in neurotrophic keratitis
5





















